trial_id
stringlengths 11
11
| question
stringlengths 154
5.24k
| options
dict | answer
stringclasses 4
values | trials
listlengths 4
4
| id
int64 0
27.3k
| split
stringclasses 2
values |
|---|---|---|---|---|---|---|
NCT00007501
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications
Brief Summary: The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60. Even without complications, HZ can interfere with an elderly patient's ability to perform essential activities of daily living, resulting in a loss of independence that is emotionally devastating and frequently irreversible. The most common complication of HZ in elderly persons is postherpetic neuralgia (PHN), which frequently results in disordered sleep, chronic fatigue, anxiety and severe depression. Antiviral therapy has a modest impact on the acute phase of HZ. However, it does not appear to prevent the development of PHN.
This study is a 5.5 year randomized, double-blind, placebo-controlled, efficacy trial to determine whether vaccination with live-attenuated Oka/Merck varicella-zoster decreases the incidence and/or severity of herpes zoster (HZ) and its complications in adults 60 years of age and older.
|
{
"A": "Arm Label: GSK1437173A _LD Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK1437173A Low Dose | Arm Label: GSK1437173A _MD Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK1437173A Medium Dose | Arm Label: GSK1437173A _HD Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK1437173A High Dose | Arm Label: Placebo + GSK1437173A _HD Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK1437173A High Dose, Biological: Placebo | Arm Label: GSK1437173A_MODIFIED GROUP; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK1437173A Modified | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A Low Dose; Assigned to Arm(s): GSK1437173A _LD Group | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A Medium Dose; Assigned to Arm(s): GSK1437173A _MD Group | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A High Dose; Assigned to Arm(s): GSK1437173A _HD Group, Placebo + GSK1437173A _HD Group | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A Modified; Assigned to Arm(s): GSK1437173A_MODIFIED GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo + GSK1437173A _HD Group",
"B": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2",
"C": "Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group",
"D": "Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3"
}
|
B
|
[
"NCT00434577",
"NCT00007501",
"NCT00492648",
"NCT00561080"
] | 300 |
train
|
NCT00007657
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
Brief Summary: PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI.
|
{
"A": "Arm Label: Saxagliptin 2.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 10 mg (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Placebo (D); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching Saxagliptin, Drug: Metformin | Arm Label: Open-Label Treatment Cohort (Direct Enrollees) (E); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 10 mg (C) | Intervention Type: DRUG; Name: Placebo matching Saxagliptin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Placebo matching Metformin; Assigned to Arm(s): Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E), Placebo (D), Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B)",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Intensive medical therapy, Procedure: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intensive medical therapy | Intervention Type: PROCEDURE; Name: Intensive medical therapy; Assigned to Arm(s): 1, 2 | Intervention Type: PROCEDURE; Name: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy; Assigned to Arm(s): 1",
"C": "Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00121641",
"NCT00007657",
"NCT00819091",
"NCT00360815"
] | 301 |
train
|
NCT00007683
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)
Brief Summary: Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events).
|
{
"A": "Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg",
"B": "Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)",
"C": "Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): warfarin",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3"
}
|
D
|
[
"NCT01877915",
"NCT00571649",
"NCT00041938",
"NCT00007683"
] | 302 |
train
|
NCT00007683
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)
Brief Summary: Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events).
|
{
"A": "Intervention Type: DRUG; Name: anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin and dipyridamole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin alone; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3",
"C": "Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00161070",
"NCT00007683",
"NCT00109382",
"NCT00050817"
] | 303 |
train
|
NCT00007761
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #430 - Reducing The Efficacy-Effectiveness Gap In Bipolar Disorder
Brief Summary: Based on highly promising preliminary data, it is proposed to conduct a multi-site randomized controlled trial of a high-intensity ambulatory treatment program for bipolar disorder against standard office-based, physician-centered care. The major characteristics of this program are that it emphasizes (1) aggressive guideline-driven pharmacotherapy, (2) continuity of care with identified primary mental health nurse clinicians supported by psychiatrist back-up, and (3) patient education to improve treatment alliance and illness management skills.
|
{
"A": "Arm Label: A Helping Hand (AHH); Type: EXPERIMENTAL; Interventions: Behavioral: Self-care management | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-care management; Assigned to Arm(s): A Helping Hand (AHH)",
"B": "Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Reverse Colocated Integrated Care | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Reverse Colocated Integrated Care; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Control Group",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bipolar Disorder Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual (psychiatric) Care | Intervention Type: BEHAVIORAL; Name: Bipolar Disorder Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual (psychiatric) Care; Assigned to Arm(s): 2",
"D": "Arm Label: TEAMcare treatment of diabetes; Type: ACTIVE_COMPARATOR; Interventions: Other: TEAMcare treatment of diabetes | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: TEAMcare treatment of diabetes; Assigned to Arm(s): TEAMcare treatment of diabetes"
}
|
C
|
[
"NCT02147522",
"NCT03881657",
"NCT00007761",
"NCT02011529"
] | 304 |
train
|
NCT00009529
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To examine the effects of rigid gas permeable contact lenses on the progression of myopia (nearsightedness) in children
To determine what changes in the eyes cause certain eyes to progress in nearsightedness more slowly
|
{
"A": "Arm Label: Biofinity; Type: ACTIVE_COMPARATOR; Interventions: Device: Biofinity | Arm Label: Biofinity Multifocal D +1.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +1.50 add | Arm Label: Biofinity Multifocal D +2.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +1.50 add; Assigned to Arm(s): Biofinity Multifocal D +1.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +2.50 add; Assigned to Arm(s): Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity; Assigned to Arm(s): Biofinity",
"B": "N/A",
"C": "Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle",
"D": "Intervention Type: DRUG; Name: 7-methylxanthine; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT02255474",
"NCT00009529",
"NCT00522288",
"NCT00263471"
] | 305 |
train
|
NCT00009633
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Visit of High Risk Infants
Brief Summary: The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.
|
{
"A": "Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®",
"B": "Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control",
"C": "Arm Label: Pneumostem®; Type: N/A; Interventions: Biological: Pneumostem® | Intervention Type: BIOLOGICAL; Name: Pneumostem®; Assigned to Arm(s): Pneumostem®",
"D": "Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort"
}
|
D
|
[
"NCT01297205",
"NCT00593242",
"NCT01632475",
"NCT00009633"
] | 306 |
train
|
NCT00009646
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)
Brief Summary: This trial was to determine whether giving low-dose indomethacin to infants weight 500 to 999 grams (approximately 1 to 2 pounds) at birth improves their survival without cerebral palsy or developmental problems at 18 to 22 months of age.
|
{
"A": "Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control",
"B": "Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline",
"C": "Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A",
"D": "Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
D
|
[
"NCT00334737",
"NCT00413946",
"NCT01207778",
"NCT00009646"
] | 307 |
train
|
NCT00009646
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)
Brief Summary: This trial was to determine whether giving low-dose indomethacin to infants weight 500 to 999 grams (approximately 1 to 2 pounds) at birth improves their survival without cerebral palsy or developmental problems at 18 to 22 months of age.
|
{
"A": "Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A",
"C": "Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control",
"D": "Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
D
|
[
"NCT01441427",
"NCT01207778",
"NCT00334737",
"NCT00009646"
] | 308 |
train
|
NCT00009945
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy
Brief Summary: RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and other parts of the body. It is not yet known whether clodronate is more effective alone or combined with chemotherapy and /or hormonal therapy in preventing metastatic breast cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of clodronate with or without chemotherapy and /or hormonal therapy in preventing metastases in women who have stage I or stage II breast cancer.
|
{
"A": "Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: risedronate (including placebo) | Intervention Type: DRUG; Name: risedronate (including placebo); Assigned to Arm(s): A",
"B": "Arm Label: AZ (Arimidex+Zoledronate); Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole, Drug: zoledronic acid, Other: goserelin | Arm Label: TZ (Tamoxifen+Zoledronate); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: zoledronic acid, Other: goserelin | Arm Label: AC (Arimidex Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole, Other: goserelin | Arm Label: TC (Tamoxifen Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Other: goserelin | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): TC (Tamoxifen Control), TZ (Tamoxifen+Zoledronate) | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): AC (Arimidex Control), AZ (Arimidex+Zoledronate) | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): AZ (Arimidex+Zoledronate), TZ (Tamoxifen+Zoledronate) | Intervention Type: OTHER; Name: goserelin; Assigned to Arm(s): AC (Arimidex Control), AZ (Arimidex+Zoledronate), TC (Tamoxifen Control), TZ (Tamoxifen+Zoledronate)",
"C": "Arm Label: Arm 1: Clodronate; Type: EXPERIMENTAL; Interventions: Drug: clodronate | Arm Label: Arm 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: clodronate; Assigned to Arm(s): Arm 1: Clodronate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 2: Placebo",
"D": "Arm Label: Ibandronic Acid; Type: EXPERIMENTAL; Interventions: Drug: ibandronate sodium | Arm Label: Zoledronic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid, Drug: Zolendronic Acid | Intervention Type: DRUG; Name: ibandronate sodium; Assigned to Arm(s): Ibandronic Acid | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronic Acid | Intervention Type: DRUG; Name: Zolendronic Acid; Assigned to Arm(s): Zoledronic Acid"
}
|
C
|
[
"NCT00118508",
"NCT00295646",
"NCT00009945",
"NCT00326820"
] | 309 |
train
|
NCT00010244
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy is more effective for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of radiation therapy in treating patients who have localized prostate cancer.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Gray | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Radiation: Gray | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 2",
"B": "Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"C": "Arm Label: Radical prostatectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radical prostatectomy | Arm Label: Conformal radiation therapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conformal radiation therapy | Arm Label: Active monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Active monitoring | Intervention Type: PROCEDURE; Name: Radical prostatectomy; Assigned to Arm(s): Radical prostatectomy | Intervention Type: RADIATION; Name: Conformal radiation therapy; Assigned to Arm(s): Conformal radiation therapy | Intervention Type: OTHER; Name: Active monitoring; Assigned to Arm(s): Active monitoring",
"D": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I, Arm II"
}
|
B
|
[
"NCT00692107",
"NCT00010244",
"NCT02044172",
"NCT00967863"
] | 310 |
train
|
NCT00010517
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acupuncture in the Treatment of Depression
Brief Summary: The current large randomized placebo-controlled trial is testing the ability of acupuncture to treat major depression. The study is unique in that treatment effects will be from the perspective of both Western psychiatry and Chinese medicine.
|
{
"A": "Arm Label: Behavioral based In-home Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Based In-Home Intervention | Intervention Type: BEHAVIORAL; Name: Behavioral Based In-Home Intervention; Assigned to Arm(s): Behavioral based In-home Intervention",
"B": "Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A",
"C": "Arm Label: NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Arm Label: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Academic Counseling | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): NET | Intervention Type: BEHAVIORAL; Name: Academic Counseling; Assigned to Arm(s): AC",
"D": "Arm Label: Minimal Contact Control; Type: OTHER; Interventions: Behavioral: Minimal Contact Control | Arm Label: PE-Massed; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure Therapy - Massed | Arm Label: PE-Spaced; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolonged Exposure Therapy - Spaced | Arm Label: Present-Centered Therapy (PCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy - Massed; Assigned to Arm(s): PE-Massed | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy - Spaced; Assigned to Arm(s): PE-Spaced | Intervention Type: BEHAVIORAL; Name: Minimal Contact Control; Assigned to Arm(s): Minimal Contact Control | Intervention Type: BEHAVIORAL; Name: Present-Centered Therapy; Assigned to Arm(s): Present-Centered Therapy (PCT)"
}
|
B
|
[
"NCT00511680",
"NCT00010517",
"NCT00552006",
"NCT01049516"
] | 311 |
train
|
NCT00010517
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acupuncture in the Treatment of Depression
Brief Summary: The current large randomized placebo-controlled trial is testing the ability of acupuncture to treat major depression. The study is unique in that treatment effects will be from the perspective of both Western psychiatry and Chinese medicine.
|
{
"A": "Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A",
"B": "Arm Label: Traditional Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Minimal Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Other: Acupuncture | Arm Label: Placebo Acupuncture; Type: PLACEBO_COMPARATOR; Interventions: Other: Acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Minimal Acupuncture, Placebo Acupuncture, Traditional Acupuncture",
"C": "Arm Label: DCEAS; Type: EXPERIMENTAL; Interventions: Procedure: DCEAS (Hwato®/ Dongbang®), Procedure: Body electro-acupuncture (Hwato®/ Dongbang®), Drug: Fluoxetine | Arm Label: n-CEA; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Body electro-acupuncture (Hwato®/ Dongbang®), Procedure: n-CEA (Strietberger®), Drug: Fluoxetine | Intervention Type: PROCEDURE; Name: DCEAS (Hwato®/ Dongbang®); Assigned to Arm(s): DCEAS | Intervention Type: PROCEDURE; Name: Body electro-acupuncture (Hwato®/ Dongbang®); Assigned to Arm(s): DCEAS, n-CEA | Intervention Type: PROCEDURE; Name: n-CEA (Strietberger®); Assigned to Arm(s): n-CEA | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): DCEAS, n-CEA",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Sham; Assigned to Arm(s): 2"
}
|
A
|
[
"NCT00010517",
"NCT00838994",
"NCT01174394",
"NCT00071110"
] | 312 |
train
|
NCT00011193
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose-response to Exercise in Women Aged 45-75 Years (DREW)
Brief Summary: To investigate the effects of different amounts of exercise on both cardiorespiratory fitness and risk factors for cardiovascular disease in sedentary, overweight, mildly hypertensive, but healthy, postmenopausal women aged 45 to 75 years.
|
{
"A": "Arm Label: Non-Exercise Control Group; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 4-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 8-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 12-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 12-kcal/kg Energy Expenditure per week, 4-kcal/kg Energy Expenditure per week, 8-kcal/kg Energy Expenditure per week, Non-Exercise Control Group",
"B": "Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Behavioral: Yoga, Behavioral: Exercise, Behavioral: Usual Activity | Arm Label: Omega-3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3, Behavioral: Yoga, Behavioral: Exercise, Behavioral: Usual Activity | Arm Label: Yoga; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo, Dietary Supplement: Omega-3, Behavioral: Yoga | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo, Dietary Supplement: Omega-3, Behavioral: Exercise | Arm Label: Usual Activity 1; Type: OTHER; Interventions: Dietary Supplement: Placebo, Dietary Supplement: Omega-3, Behavioral: Usual Activity | Arm Label: Usual Activity 2; Type: OTHER; Interventions: Dietary Supplement: Placebo, Dietary Supplement: Omega-3, Behavioral: Usual Activity | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Exercise, Placebo, Usual Activity 1, Usual Activity 2, Yoga | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3; Assigned to Arm(s): Exercise, Omega-3, Usual Activity 1, Usual Activity 2, Yoga | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): Omega-3, Placebo, Yoga | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise, Omega-3, Placebo | Intervention Type: BEHAVIORAL; Name: Usual Activity; Assigned to Arm(s): Omega-3, Placebo, Usual Activity 1, Usual Activity 2",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00011193",
"NCT00091988",
"NCT01178892",
"NCT00000611"
] | 313 |
train
|
NCT00011193
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose-response to Exercise in Women Aged 45-75 Years (DREW)
Brief Summary: To investigate the effects of different amounts of exercise on both cardiorespiratory fitness and risk factors for cardiovascular disease in sedentary, overweight, mildly hypertensive, but healthy, postmenopausal women aged 45 to 75 years.
|
{
"A": "Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise",
"B": "Intervention Type: BEHAVIORAL; Name: Supervised Exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Home-Based Exercise; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline (Zoloft); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A",
"D": "Arm Label: Non-Exercise Control Group; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 4-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 8-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 12-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 12-kcal/kg Energy Expenditure per week, 4-kcal/kg Energy Expenditure per week, 8-kcal/kg Energy Expenditure per week, Non-Exercise Control Group"
}
|
D
|
[
"NCT00476567",
"NCT00331305",
"NCT00103415",
"NCT00011193"
] | 314 |
train
|
NCT00011986
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
Brief Summary: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
|
{
"A": "Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: azithromycin (drug); Assigned to Arm(s): N/A",
"D": "Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pegylated Liposomal Doxorubicin Hydrochloride | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Topotecan Hydrochloride | Arm Label: Arm V; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm II, Arm V | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: Topotecan Hydrochloride; Assigned to Arm(s): Arm IV | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm V"
}
|
D
|
[
"NCT00144339",
"NCT00857038",
"NCT00323986",
"NCT00011986"
] | 315 |
train
|
NCT00011986
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
Brief Summary: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
|
{
"A": "Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pegylated Liposomal Doxorubicin Hydrochloride | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Topotecan Hydrochloride | Arm Label: Arm V; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm II, Arm V | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: Topotecan Hydrochloride; Assigned to Arm(s): Arm IV | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm V",
"B": "Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo",
"C": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Avelox (Moxifloxacin, BAY12-8039); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2",
"D": "Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00011986",
"NCT00760838",
"NCT00473460",
"NCT01071161"
] | 316 |
train
|
NCT00011986
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
Brief Summary: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
|
{
"A": "Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pegylated Liposomal Doxorubicin Hydrochloride | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Topotecan Hydrochloride | Arm Label: Arm V; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm II, Arm V | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: Topotecan Hydrochloride; Assigned to Arm(s): Arm IV | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm V",
"B": "Intervention Type: DRUG; Name: Intravenous Clarithromycin; Assigned to Arm(s): N/A",
"C": "Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): Clarithromycin, Placebo",
"D": "Arm Label: erythromycin; Type: EXPERIMENTAL; Interventions: Drug: Erythromycin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): erythromycin"
}
|
A
|
[
"NCT00011986",
"NCT00297674",
"NCT00121550",
"NCT01659619"
] | 317 |
train
|
NCT00012558
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
Brief Summary: A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies.
|
{
"A": "Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: valproate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: inositol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family-focused Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Interpersonal and Social Rhythms Therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: A Helping Hand (AHH); Type: EXPERIMENTAL; Interventions: Behavioral: Self-care management | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-care management; Assigned to Arm(s): A Helping Hand (AHH)",
"C": "Arm Label: Collaborative shared care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative shared care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Collaborative shared care | Intervention Type: BEHAVIORAL; Name: Collaborative shared care; Assigned to Arm(s): Collaborative shared care, Usual care",
"D": "Arm Label: Virtual Learning Collaborative; Type: EXPERIMENTAL; Interventions: Other: Virtual Learning Collaborative | Arm Label: Technical Assistance; Type: ACTIVE_COMPARATOR; Interventions: Other: Technical Assistance | Intervention Type: OTHER; Name: Virtual Learning Collaborative; Assigned to Arm(s): Virtual Learning Collaborative | Intervention Type: OTHER; Name: Technical Assistance; Assigned to Arm(s): Technical Assistance"
}
|
A
|
[
"NCT00012558",
"NCT02147522",
"NCT02895269",
"NCT03891368"
] | 318 |
train
|
NCT00013611
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)
Brief Summary: This study will examine whether interleukin-2 (IL-2) plus antiretroviral therapy (ART) slows HIV disease progression in patients with low CD4+ T cell counts compared with patients taking ART alone. CD4+ T cells are a subset of lymphocytes-white blood cells that are part of the body's immune system. IL-2 is a protein that is naturally produced by lymphocytes. Given in intermittent cycles, IL-2 can raise CD4+ T cell counts in some HIV-infected patients taking antiretroviral drugs. This study will examine whether the increase in CD4+ T cells lowers the risk of AIDS-related illnesses and death.
HIV-infected patients 18 years of age and older with a viral load under 10,000 copies per milliliter and a CD4+ T cell count between 50 and 299 cells per cubic millimeter who are taking antiretroviral therapy and who have not previously received IL-2 therapy may be eligible for this study. Candidates will be screened with a medical history, physical examination, and blood and urine tests. Participation in the study will be from 4.5 to 6 years, depending on what point in the duration of the study the individual patient is enrolled.
Patients will be randomly assigned to receive IL-2 plus ART or ART alone. All participants will be advised individually about the best ART regimen for them. Patients in the IL-2 treatment group will be taught how to self-inject IL-2 under the skin (similar to insulin injections). They will inject IL-2 twice a day for 5 days every 8 weeks for the first year (until week 49 of the study). From week 49 on they may receive 5-day cycles of IL-2 every 4 months when needed to maintain CD4+ T cell count elevations. An extra cycle may be given 2 months after the week 49 follow-up visit (see follow-up schedule below), depending on their CD4+ T cell count. Patients whose cell counts have not increased after 12 to 16 months of IL-2 treatment will discuss with the doctor the possibility of stopping IL-2. Those who do stop IL-2 treatment will be asked to remain in the study for follow-up evaluations.
All patients will be followed in the clinic every 2 months for the first year of the study (weeks 1, 9, 17, 25, 33, 41 and 49) and every 4 months during years 2-6 for a brief history and physical exam, urine and blood tests, return of diary cards (record of drug side effects) and medication review. During the visits from the second year on, patients will also be asked about their ability to do certain ordinary tasks, such as taking care of themselves; ...
|
{
"A": "Arm Label: Antiretroviral therapy alone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proleukin plus antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Drug: Proleukin | Intervention Type: DRUG; Name: Proleukin; Assigned to Arm(s): Proleukin plus antiretroviral therapy",
"B": "Intervention Type: DRUG; Name: Indinavir sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): N/A",
"C": "Arm Label: No IL-2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IL-2 without ART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Arm Label: IL-2 with pericycle HAART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Intervention Type: DRUG; Name: IL-2; Assigned to Arm(s): IL-2 with pericycle HAART, IL-2 without ART",
"D": "Arm Label: rIL-2; Type: EXPERIMENTAL; Interventions: Drug: Recombinant interleukin-2 (rIL-2) | Arm Label: No rIL-2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant interleukin-2 (rIL-2); Assigned to Arm(s): rIL-2"
}
|
A
|
[
"NCT00013611",
"NCT00000923",
"NCT00110812",
"NCT00004978"
] | 319 |
train
|
NCT00013871
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated With Highly Active Antiretroviral Therapy (HAART)
Brief Summary: The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus.
Pneumococcal infections are the most common AIDS-related infection in HIV-infected children. PCV may help reduce the chances of HIV-infected children getting pneumococcal infections. This study will look at whether pneumococcal vaccines are safe and effective in HIV-infected children receiving HAART. It will look at whether HIV-infected children are protected by childhood vaccines received previously and if more doses are safe and improve protection.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Recombivax | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Twinrix | Intervention Type: BIOLOGICAL; Name: Recombivax; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Twinrix; Assigned to Arm(s): 2",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: ALVAC-HIV vCP1521 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: ALVAC HIV-1 vCP1521 | Intervention Type: BIOLOGICAL; Name: ALVAC-HIV vCP1521; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: ALVAC HIV-1 vCP1521; Assigned to Arm(s): 2",
"C": "Intervention Type: BIOLOGICAL; Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Measles-Mumps-Rubella Vaccine (Live); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Pneumococcal Vaccine, Polyvalent (23-valent); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Pneumococcal Conjugate Vaccine, Heptavalent; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Hepatitis B Vaccine (Recombinant); Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B 20 mcg | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B 40 mcg | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg | Intervention Type: BIOLOGICAL; Name: Engerix-B 20 mcg; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Engerix-B 40 mcg; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg; Assigned to Arm(s): 3"
}
|
C
|
[
"NCT00107042",
"NCT00098163",
"NCT00013871",
"NCT00106964"
] | 320 |
train
|
NCT00014001
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)
Brief Summary: The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
|
{
"A": "Intervention Type: DRUG; Name: perphenazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clozapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluphenazine decanoate; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A",
"C": "Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): A1",
"D": "Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone"
}
|
A
|
[
"NCT00014001",
"NCT00418171",
"NCT00174447",
"NCT00932529"
] | 321 |
train
|
NCT00014001
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)
Brief Summary: The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
|
{
"A": "Arm Label: MK-0777 8 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: MK-0777 3 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 8 mg | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 3 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: perphenazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clozapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluphenazine decanoate; Assigned to Arm(s): N/A",
"C": "Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"D": "Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00505076",
"NCT00014001",
"NCT00149292",
"NCT00210717"
] | 322 |
train
|
NCT00014612
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: After Mapping Of The Axilla: Radiotherapy Or Surgery
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be a less invasive treatment and cause fewer side effects than complete axillary lymph node dissection. It is not yet known which treatment is more effective for invasive breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of complete axillary lymph node dissection with that of axillary radiation therapy in treating women who have invasive breast cancer.
|
{
"A": "Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"B": "Arm Label: Arm I: Conventional axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional surgery | Arm Label: Arm II: Sentinel node resection followed by node examination; Type: EXPERIMENTAL; Interventions: Procedure: Sentinel node resection followed by node examination | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I: Conventional axillary dissection | Intervention Type: PROCEDURE; Name: Sentinel node resection followed by node examination; Assigned to Arm(s): Arm II: Sentinel node resection followed by node examination",
"C": "Arm Label: axillary lymph node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: axillary lymph node dissection, Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery | Arm Label: axillary radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery, Radiation: radiation therapy | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): axillary lymph node dissection | Intervention Type: PROCEDURE; Name: lymphoscintigraphy; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): axillary radiotherapy",
"D": "Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00002720",
"NCT00003830",
"NCT00014612",
"NCT00210236"
] | 323 |
train
|
NCT00015002
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens
Brief Summary: A course of steroids given to a mother who is in labor with a premature fetus will reduce the risk of the premature infant dying or having serious complications. This trial will test whether more than one course of antenatal steroids is more beneficial or risky to the infant than a single course.
|
{
"A": "Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Multiple vs. single courses of antenatalcorticosteroids; Assigned to Arm(s): N/A",
"D": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B"
}
|
B
|
[
"NCT01222247",
"NCT00015002",
"NCT00187382",
"NCT00669383"
] | 324 |
train
|
NCT00015002
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens
Brief Summary: A course of steroids given to a mother who is in labor with a premature fetus will reduce the risk of the premature infant dying or having serious complications. This trial will test whether more than one course of antenatal steroids is more beneficial or risky to the infant than a single course.
|
{
"A": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B",
"B": "Intervention Type: DRUG; Name: Multiple vs. single courses of antenatalcorticosteroids; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Betamethasone sodium phos (drug); Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00669383",
"NCT00187382",
"NCT00015002",
"NCT00295464"
] | 325 |
train
|
NCT00015002
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens
Brief Summary: A course of steroids given to a mother who is in labor with a premature fetus will reduce the risk of the premature infant dying or having serious complications. This trial will test whether more than one course of antenatal steroids is more beneficial or risky to the infant than a single course.
|
{
"A": "Intervention Type: DRUG; Name: Betamethasone sodium phos (drug); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B",
"D": "Intervention Type: DRUG; Name: Multiple vs. single courses of antenatalcorticosteroids; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00295464",
"NCT00015002",
"NCT00669383",
"NCT00187382"
] | 326 |
train
|
NCT00015548
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00820859",
"NCT02035553",
"NCT00036114",
"NCT00015548"
] | 327 |
train
|
NCT00015548
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.
|
{
"A": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1",
"C": "Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care",
"D": "Arm Label: Intervention exercise; Type: EXPERIMENTAL; Interventions: Other: Intervention exercise | Arm Label: Sham exercise; Type: SHAM_COMPARATOR; Interventions: Other: Sham Exercise | Intervention Type: OTHER; Name: Intervention exercise; Assigned to Arm(s): Intervention exercise | Intervention Type: OTHER; Name: Sham Exercise; Assigned to Arm(s): Sham exercise"
}
|
A
|
[
"NCT00015548",
"NCT00675935",
"NCT02295462",
"NCT02463864"
] | 328 |
train
|
NCT00015548
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.
|
{
"A": "Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A",
"D": "Arm Label: Cholinesterase inhibitor only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholinesterase Plus Modafinil; Type: EXPERIMENTAL; Interventions: Drug: Modafinil | Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): Cholinesterase Plus Modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cholinesterase inhibitor only"
}
|
C
|
[
"NCT00417482",
"NCT00071721",
"NCT00015548",
"NCT01172145"
] | 329 |
train
|
NCT00015548
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.
|
{
"A": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A",
"B": "Arm Label: Citalopram and psychosocial intervention; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Arm Label: Placebo and psychosocial intervention; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): Citalopram and psychosocial intervention | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo and psychosocial intervention",
"C": "Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Buprenorphine plaster; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine plaster | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Buprenorphine plaster; Assigned to Arm(s): Buprenorphine plaster | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin",
"D": "Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00015548",
"NCT00898807",
"NCT01021696",
"NCT00371059"
] | 330 |
train
|
NCT00015548
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.
|
{
"A": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Brexpiprazole 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Arm Label: Brexpiprazole 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Intervention Type: DRUG; Name: Brexpiprazole, OPC-34712; Assigned to Arm(s): Brexpiprazole 1 mg, Brexpiprazole 2 mg | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Brexpiprazole, OPC-34712 | Arm Label: Brexpiprazole (flexible dose range 0.5 to 2 mg); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Intervention Type: DRUG; Name: Brexpiprazole, OPC-34712; Assigned to Arm(s): Brexpiprazole (flexible dose range 0.5 to 2 mg), Placebo"
}
|
A
|
[
"NCT00015548",
"NCT02035553",
"NCT01862640",
"NCT01922258"
] | 331 |
train
|
NCT00015548
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)
Brief Summary: The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.
|
{
"A": "Arm Label: Adderall Extended Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Arm Label: Adderall Immediate Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Intervention Type: DRUG; Name: Adderall ® Immediate Release; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First | Intervention Type: DRUG; Name: Adderall XR ®; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First",
"B": "Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00468143",
"NCT00697515",
"NCT00246220",
"NCT00015548"
] | 332 |
train
|
NCT00016744
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients
Brief Summary: We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF.
Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Part A: Pooled Placebo (Except Cohort A7); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched Placebo | Arm Label: Part A: VX-445 (Except Cohort A7); Type: EXPERIMENTAL; Interventions: Drug: VX-445 | Arm Label: Part A: VX-445 (Cohort A7); Type: EXPERIMENTAL; Interventions: Drug: VX-445 | Arm Label: Part B: Pooled Placebo (Cohort B1 to B4); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched Placebo | Arm Label: Part B: VX-445 (Cohort B1 to B4); Type: EXPERIMENTAL; Interventions: Drug: VX-445 | Arm Label: Part C: Pooled Placebo (Cohort C1 to C3); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched Placebo | Arm Label: Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3); Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: TEZ/IVA, Drug: VX-445 | Arm Label: Part D: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched Placebo | Arm Label: Part D: VX-445/TEZ/IVA TC - Low Dose; Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: TEZ/IVA, Drug: VX-445 | Arm Label: Part D: VX-445/TEZ/IVA TC - Medium Dose; Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: TEZ/IVA, Drug: VX-445 | Arm Label: Part D: VX-445/TEZ/IVA TC - High Dose; Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: TEZ/IVA, Drug: VX-445 | Arm Label: Part E: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA | Arm Label: Part E: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: TEZ/IVA, Drug: VX-445 | Arm Label: Part F: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched Placebo | Arm Label: Part F: VX-445/TEZ/VX-561 TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445, Drug: TEZ, Drug: VX-561 | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3), Part D: VX-445/TEZ/IVA TC - High Dose, Part D: VX-445/TEZ/IVA TC - Low Dose, Part D: VX-445/TEZ/IVA TC - Medium Dose, Part E: VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3), Part D: VX-445/TEZ/IVA TC - High Dose, Part D: VX-445/TEZ/IVA TC - Low Dose, Part D: VX-445/TEZ/IVA TC - Medium Dose, Part E: TEZ/IVA, Part E: VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: VX-445; Assigned to Arm(s): Part A: VX-445 (Cohort A7), Part A: VX-445 (Except Cohort A7), Part B: VX-445 (Cohort B1 to B4), Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3), Part D: VX-445/TEZ/IVA TC - High Dose, Part D: VX-445/TEZ/IVA TC - Low Dose, Part D: VX-445/TEZ/IVA TC - Medium Dose, Part E: VX-445/TEZ/IVA TC, Part F: VX-445/TEZ/VX-561 TC | Intervention Type: DRUG; Name: Matched Placebo; Assigned to Arm(s): Part A: Pooled Placebo (Except Cohort A7), Part B: Pooled Placebo (Cohort B1 to B4), Part C: Pooled Placebo (Cohort C1 to C3), Part D: Placebo, Part F: Placebo | Intervention Type: DRUG; Name: TEZ; Assigned to Arm(s): Part F: VX-445/TEZ/VX-561 TC | Intervention Type: DRUG; Name: VX-561; Assigned to Arm(s): Part F: VX-445/TEZ/VX-561 TC | Intervention Type: DRUG; Name: VX-445; Assigned to Arm(s): Part A: VX-445 (Cohort A7)",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium 4-Phenylbutyrate (4PBA), Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein), Drug: Placebo | Intervention Type: DRUG; Name: Sodium 4-Phenylbutyrate (4PBA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"D": "Arm Label: Group 1 - 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 2 - 100 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 3 - 200 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 4 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: N91115 | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): Group 1 - 50 mg, Group 2 - 100 mg, Group 3 - 200 mg, Group 4 - Placebo"
}
|
C
|
[
"NCT00865904",
"NCT03227471",
"NCT00016744",
"NCT02275936"
] | 333 |
train
|
NCT00016744
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients
Brief Summary: We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF.
Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
|
{
"A": "Arm Label: GLPG2222 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 150 mg q.d. | Arm Label: GLPG2222 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 300 mg q.d. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 150 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 1 | Intervention Type: DRUG; Name: GLPG2222 300 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium 4-Phenylbutyrate (4PBA), Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein), Drug: Placebo | Intervention Type: DRUG; Name: Sodium 4-Phenylbutyrate (4PBA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: miglustat | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: miglustat; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2",
"D": "Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA"
}
|
B
|
[
"NCT03045523",
"NCT00016744",
"NCT00742092",
"NCT04058366"
] | 334 |
train
|
NCT00017095
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Currently patients with breast cancer are treated with one of several very similar combinations of drugs. Analysis of biomarkers in tumor tissue may help doctors predict how well patients with breast cancer will respond to treatment and help doctors choose the best drug regimen to treat each patient.
PURPOSE: This randomized phase III trial is studying giving different regimens of chemotherapy and comparing how well they work in treating women with large operable or locally advanced or inflammatory breast cancer. This study is also looking at whether analyzing a specific biomarker (p53) in tumor tissue may help doctors predict how well patients will respond to treatment and help doctors choose the best drug to treat each patient.
|
{
"A": "Arm Label: BIBW 2992; Type: EXPERIMENTAL; Interventions: Drug: BIBW 2992 | Arm Label: Cisplatin/Pemetrexed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Cisplatin/Pemetrexed | Intervention Type: DRUG; Name: BIBW 2992; Assigned to Arm(s): BIBW 2992 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Cisplatin/Pemetrexed",
"B": "Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): N/A",
"C": "Arm Label: PGx-treatment; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid | Arm Label: STD-treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: isoniazed | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): PGx-treatment | Intervention Type: DRUG; Name: isoniazed; Assigned to Arm(s): STD-treatment",
"D": "Arm Label: non taxane based chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Genetic: microarray analysis, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Procedure: biopsy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: radiation therapy | Arm Label: taxane based chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: epirubicin hydrochloride, Genetic: microarray analysis, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Procedure: biopsy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): non taxane based chemotherapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): non taxane based chemotherapy | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): taxane based chemotherapy | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): non taxane based chemotherapy | Intervention Type: GENETIC; Name: microarray analysis; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: OTHER; Name: immunohistochemistry staining method; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): non taxane based chemotherapy, taxane based chemotherapy"
}
|
D
|
[
"NCT00949650",
"NCT00340080",
"NCT00298870",
"NCT00017095"
] | 335 |
train
|
NCT00017147
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. O6-benzylguanine may help carmustine kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known whether radiation therapy and carmustine are more effective with or without O6-benzylguanine.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus carmustine with or without O6-benzylguanine in treating patients who have newly diagnosed glioblastoma multiforme or gliosarcoma.
|
{
"A": "Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib",
"B": "Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy",
"C": "Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care",
"D": "Arm Label: O6-BG + BCNU + Radiation Therapy; Type: EXPERIMENTAL; Interventions: Drug: carmustine, Radiation: radiation therapy, Drug: O6-Benzylguanine | Arm Label: BCNU + Radiation Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carmustine, Radiation: radiation therapy | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): BCNU + Radiation Therapy, O6-BG + BCNU + Radiation Therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): BCNU + Radiation Therapy, O6-BG + BCNU + Radiation Therapy | Intervention Type: DRUG; Name: O6-Benzylguanine; Assigned to Arm(s): O6-BG + BCNU + Radiation Therapy"
}
|
D
|
[
"NCT00777153",
"NCT01502241",
"NCT00916409",
"NCT00017147"
] | 336 |
train
|
NCT00017225
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Combining these therapies may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with or without peripheral stem cell transplantation in treating patients who have neuroblastoma.
|
{
"A": "Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT",
"B": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"C": "Arm Label: Arm I (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Arm Label: Arm II (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm I (unpurged PBSC collection) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: isotretinoin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: topotecan hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: bone marrow ablation with stem cell support; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection)",
"D": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT01704716",
"NCT00017225",
"NCT00004188",
"NCT00002803"
] | 337 |
train
|
NCT00017225
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Combining these therapies may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with or without peripheral stem cell transplantation in treating patients who have neuroblastoma.
|
{
"A": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"B": "Arm Label: Arm I (isotretinoin) (closed to accrual as of 4/16/2009); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: Dinutuximab, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Biological: Sargramostim | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: DRUG; Name: Isotretinoin; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)",
"C": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"D": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00365755",
"NCT00026312",
"NCT00002803",
"NCT00017225"
] | 338 |
train
|
NCT00017303
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.
|
{
"A": "Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin",
"B": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oglufanide disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"C": "Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab",
"D": "Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm"
}
|
B
|
[
"NCT00350948",
"NCT00017303",
"NCT00976911",
"NCT01837251"
] | 339 |
train
|
NCT00017303
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.
|
{
"A": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oglufanide disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"B": "Arm Label: Carboplatin plus PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pegylated Lipoxomal Doxorubicin (PLD) | Arm Label: Trabectedin plus PLD; Type: EXPERIMENTAL; Interventions: Drug: Pegylated Lipoxomal Doxorubicin (PLD), Drug: Trabectedin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin plus PLD | Intervention Type: DRUG; Name: Pegylated Lipoxomal Doxorubicin (PLD); Assigned to Arm(s): Carboplatin plus PLD, Trabectedin plus PLD | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Trabectedin plus PLD",
"C": "Arm Label: Paclitaxel/Carboplatin/Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin",
"D": "Arm Label: Bevacizumab+TC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: TC:paclitaxel + carboplatin | Arm Label: TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: TC:paclitaxel + carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab+TC | Intervention Type: DRUG; Name: TC:paclitaxel + carboplatin; Assigned to Arm(s): Bevacizumab+TC, TC"
}
|
A
|
[
"NCT00017303",
"NCT01379989",
"NCT00390611",
"NCT01838538"
] | 340 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP",
"B": "Intervention Type: DRUG; Name: Naproxen Sodium (Aleve); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT01206062",
"NCT00007189",
"NCT00017953",
"NCT00122811"
] | 341 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: CLOSE guided PVI and insertable cardiac monitor; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation; Assigned to Arm(s): CLOSE guided PVI and insertable cardiac monitor",
"B": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"C": "Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE",
"D": "Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy"
}
|
B
|
[
"NCT02925624",
"NCT00017953",
"NCT01203748",
"NCT00911508"
] | 342 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: AIT: aerobic interval training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic interval training | Arm Label: MIT, moderate intensity training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: moderate intensity training | Arm Label: Recommendation of regular exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendation of regular exercise | Intervention Type: BEHAVIORAL; Name: Aerobic interval training; Assigned to Arm(s): AIT: aerobic interval training | Intervention Type: BEHAVIORAL; Name: moderate intensity training; Assigned to Arm(s): MIT, moderate intensity training | Intervention Type: BEHAVIORAL; Name: Recommendation of regular exercise; Assigned to Arm(s): Recommendation of regular exercise",
"B": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"C": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise - Continuous Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Continuous Walking | Arm Label: Exercise - Interval Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise Training - Interval Walking; Assigned to Arm(s): Exercise - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise - Continuous Walking; Assigned to Arm(s): Exercise - Continuous Walking",
"D": "Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise"
}
|
B
|
[
"NCT00218972",
"NCT00017953",
"NCT01234155",
"NCT01418027"
] | 343 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Podcasting + mobile media; Type: EXPERIMENTAL; Interventions: Behavioral: Podcasting + mobile media | Arm Label: Podcasting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Podcasting + mobile media | Intervention Type: BEHAVIORAL; Name: Podcasting + mobile media; Assigned to Arm(s): Podcasting, Podcasting + mobile media",
"B": "Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight.; Assigned to Arm(s): N/A",
"D": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education"
}
|
D
|
[
"NCT01139255",
"NCT00435240",
"NCT00202748",
"NCT00017953"
] | 344 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Care; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, amlodipine, hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil, amlodipine, hydrochlorothiazide; Assigned to Arm(s): Experimental Care",
"D": "Arm Label: Aerobic Exercise (Ex); Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training, Other: Usual Care | Arm Label: Intensive Reduction of Vascular Risk Factors (IRVR); Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Stretching Exercise | Arm Label: IRVR+Ex; Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care, Behavioral: Stretching Exercise | Intervention Type: DRUG; Name: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine); Assigned to Arm(s): IRVR+Ex, Intensive Reduction of Vascular Risk Factors (IRVR) | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Aerobic Exercise (Ex), IRVR+Ex | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Aerobic Exercise (Ex), Usual Care | Intervention Type: BEHAVIORAL; Name: Stretching Exercise; Assigned to Arm(s): Intensive Reduction of Vascular Risk Factors (IRVR), Usual Care"
}
|
A
|
[
"NCT00017953",
"NCT00000620",
"NCT02377661",
"NCT02913664"
] | 345 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"B": "Arm Label: diet following American Diabetes Association guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: diet following ADA guidelines | Arm Label: vegan diet; Type: EXPERIMENTAL; Interventions: Other: vegan diet | Intervention Type: OTHER; Name: vegan diet; Assigned to Arm(s): vegan diet | Intervention Type: OTHER; Name: diet following ADA guidelines; Assigned to Arm(s): diet following American Diabetes Association guidelines",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2",
"D": "Arm Label: Eco-Atkins diet; Type: EXPERIMENTAL; Interventions: Other: Eco-Atkins diet (high vegetable protein and vegetable fat) | Arm Label: NCEP diet; Type: ACTIVE_COMPARATOR; Interventions: Other: NCEP diet | Intervention Type: OTHER; Name: Eco-Atkins diet (high vegetable protein and vegetable fat); Assigned to Arm(s): Eco-Atkins diet | Intervention Type: OTHER; Name: NCEP diet; Assigned to Arm(s): NCEP diet"
}
|
A
|
[
"NCT00017953",
"NCT01222429",
"NCT00276939",
"NCT00256516"
] | 346 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Balance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Behavioral Weight Loss Program; Assigned to Arm(s): Lifestyle Balance",
"B": "Arm Label: Lifestyle intervention to increase physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: lifestyle intervention to increase physical activity | Arm Label: waiting control group; Type: NO_INTERVENTION; Interventions: Behavioral: lifestyle intervention to increase physical activity | Intervention Type: BEHAVIORAL; Name: lifestyle intervention to increase physical activity; Assigned to Arm(s): Lifestyle intervention to increase physical activity, waiting control group",
"C": "Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE",
"D": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education"
}
|
D
|
[
"NCT00344500",
"NCT00980863",
"NCT02090335",
"NCT00017953"
] | 347 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Group | Intervention Type: BEHAVIORAL; Name: Exercise Group; Assigned to Arm(s): Exercise Group",
"B": "Arm Label: Physical & Behavioral Therapy Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy (PT) and Behavioral Therapy (BT) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy (PT) and Behavioral Therapy (BT); Assigned to Arm(s): Physical & Behavioral Therapy Group",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Arm Label: Total Control Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Total Control Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Total Control Program; Assigned to Arm(s): Total Control Program"
}
|
C
|
[
"NCT02420288",
"NCT01672697",
"NCT00017953",
"NCT02334397"
] | 348 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Aerobic and Resistance, Behavioral: Dietary - Caloric Restriction | Arm Label: Dairy Protein; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Aerobic and Resistance, Behavioral: Dietary - Caloric Restriction | Arm Label: High Dairy Protein; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Aerobic and Resistance, Behavioral: Dietary - Caloric Restriction | Intervention Type: BEHAVIORAL; Name: Exercise - Aerobic and Resistance; Assigned to Arm(s): Control, Dairy Protein, High Dairy Protein | Intervention Type: BEHAVIORAL; Name: Dietary - Caloric Restriction; Assigned to Arm(s): Control, Dairy Protein, High Dairy Protein",
"B": "Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline"
}
|
C
|
[
"NCT00710398",
"NCT00868387",
"NCT00017953",
"NCT02062424"
] | 349 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo",
"B": "Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitoring and Case Management; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemonitoring, Other: Case Management | Intervention Type: DEVICE; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring and Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Telemonitoring and Case Management",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00069784",
"NCT02721667",
"NCT00017953",
"NCT00220441"
] | 350 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Usual Care Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Only | Arm Label: Vida Sana; Type: EXPERIMENTAL; Interventions: Behavioral: Vida Sana | Intervention Type: BEHAVIORAL; Name: Vida Sana; Assigned to Arm(s): Vida Sana | Intervention Type: OTHER; Name: Usual Care Only; Assigned to Arm(s): Usual Care Only",
"B": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"C": "Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): N/A",
"D": "Arm Label: Short Message Service (SMS); Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Service (SMS) | Arm Label: Standard usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Short Message Service (SMS); Assigned to Arm(s): Short Message Service (SMS)"
}
|
B
|
[
"NCT02459691",
"NCT00017953",
"NCT00409422",
"NCT01556880"
] | 351 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Individual Telephone Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Individual telephone intervention | Arm Label: Group Telephone Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group telephone intervention | Intervention Type: BEHAVIORAL; Name: Individual telephone intervention; Assigned to Arm(s): Individual Telephone Intervention | Intervention Type: BEHAVIORAL; Name: Group telephone intervention; Assigned to Arm(s): Group Telephone Intervention",
"B": "Intervention Type: BEHAVIORAL; Name: To change structure and roles of primary care teams to optimize prevention of obesity; Assigned to Arm(s): N/A",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2"
}
|
C
|
[
"NCT00749606",
"NCT00377767",
"NCT00017953",
"NCT00115063"
] | 352 |
train
|
NCT00017953
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.
|
{
"A": "Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training",
"B": "Intervention Type: BEHAVIORAL; Name: Self-management; Assigned to Arm(s): N/A",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Arm Label: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Other: Yoga Therapy Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Yoga Therapy Program; Assigned to Arm(s): Yoga Therapy"
}
|
C
|
[
"NCT01243554",
"NCT00270309",
"NCT00017953",
"NCT01672190"
] | 353 |
train
|
NCT00018005
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure Adherence and Retention Trial (HART)
Brief Summary: This study will test whether a self-management (SM) intervention, compared to usual care, will reduce the risk for adverse clinical outcome in patients with mild to moderate heart failure.
|
{
"A": "Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-coordinated integrated care model for AF | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nurse-coordinated integrated care model for AF; Assigned to Arm(s): Intervention group",
"B": "Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual Communities of practice | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Virtual Communities of practice; Assigned to Arm(s): Intervention group",
"C": "Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A",
"D": "Arm Label: Cardiac Rehabilitation Peer Mentorship; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Rehabilitation Peer Mentorship | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation Peer Mentorship; Assigned to Arm(s): Cardiac Rehabilitation Peer Mentorship"
}
|
C
|
[
"NCT03924739",
"NCT03959631",
"NCT00018005",
"NCT02204449"
] | 354 |
train
|
NCT00018005
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure Adherence and Retention Trial (HART)
Brief Summary: This study will test whether a self-management (SM) intervention, compared to usual care, will reduce the risk for adverse clinical outcome in patients with mild to moderate heart failure.
|
{
"A": "Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: 12-week Tai Chi Program | Arm Label: Heart Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12-week Education Program | Intervention Type: BEHAVIORAL; Name: 12-week Tai Chi Program; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: 12-week Education Program; Assigned to Arm(s): Heart Health Education",
"B": "Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A",
"C": "Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational support only | Arm Label: Wii Group; Type: EXPERIMENTAL; Interventions: Behavioral: Structured access to a Wii game computer (Wii) | Intervention Type: BEHAVIORAL; Name: Structured access to a Wii game computer (Wii); Assigned to Arm(s): Wii Group | Intervention Type: BEHAVIORAL; Name: Motivational support only; Assigned to Arm(s): Control Group",
"D": "Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention"
}
|
B
|
[
"NCT00110227",
"NCT00018005",
"NCT01785121",
"NCT03041610"
] | 355 |
train
|
NCT00018005
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure Adherence and Retention Trial (HART)
Brief Summary: This study will test whether a self-management (SM) intervention, compared to usual care, will reduce the risk for adverse clinical outcome in patients with mild to moderate heart failure.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A",
"D": "Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00018005",
"NCT00217945",
"NCT00149526",
"NCT00192556"
] | 356 |
train
|
NCT00018148
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Brief Summary: Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
|
{
"A": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2",
"C": "Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)",
"D": "Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
B
|
[
"NCT00044434",
"NCT00018148",
"NCT01771627",
"NCT01010204"
] | 357 |
train
|
NCT00018148
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Brief Summary: Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
|
{
"A": "Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Bupropion SR; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: smoking cessation counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Behavioral: smoking cessation counseling | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: smoking cessation counseling; Assigned to Arm(s): Bupropion SR, Placebo",
"C": "Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01244061",
"NCT01875172",
"NCT02271919",
"NCT00018148"
] | 358 |
train
|
NCT00018148
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Brief Summary: Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
|
{
"A": "Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo",
"C": "Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01370356",
"NCT00567320",
"NCT00689611",
"NCT00018148"
] | 359 |
train
|
NCT00018148
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Brief Summary: Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2",
"B": "Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"D": "Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Nicotine gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Bupropion+Nicotine Gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Double placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion, Bupropion+Nicotine Gum, Double placebo, Nicotine gum"
}
|
A
|
[
"NCT00018148",
"NCT01800019",
"NCT00018174",
"NCT00063323"
] | 360 |
train
|
NCT00018148
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Brief Summary: Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
|
{
"A": "Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm",
"B": "Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2",
"D": "Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo"
}
|
C
|
[
"NCT00644969",
"NCT00948649",
"NCT00018148",
"NCT00835900"
] | 361 |
train
|
NCT00018174
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
Brief Summary: This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
|
{
"A": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00044434",
"NCT00018174",
"NCT00150241",
"NCT00150254"
] | 362 |
train
|
NCT00018174
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
Brief Summary: This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"B": "Arm Label: Varenicline + Placebo Patch; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Placebo Patch, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Arm Label: Nicotine Patch + Placebo Tablet; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: DRUG; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Placebo Tablet; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: BEHAVIORAL; Name: Counseling Sessions; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Lab Session; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Saliva Test; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch",
"C": "Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug",
"D": "Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR"
}
|
A
|
[
"NCT00018174",
"NCT02162849",
"NCT01772641",
"NCT00935818"
] | 363 |
train
|
NCT00018174
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
Brief Summary: This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"B": "Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch",
"C": "Arm Label: Tailored Intervention Group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch, Behavioral: Tailored behavioral intervention, Drug: Nicotine replacement therapy - nicotine gum, Drug: Nicotine replacement therapy - nicotine lozenge, Drug: Bupropion Sustained Release, Drug: Varenicline, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion, Behavioral: Alcohol use risk reduction, Behavioral: Behavioral activation for the treatment of depression, Behavioral: Behavioral management of post-cessation weight gain | Arm Label: Enhanced Standard of Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch, Behavioral: Tobacco quit line referral, Drug: Nicotine replacement therapy - nicotine gum, Drug: Nicotine replacement therapy - nicotine lozenge, Drug: Bupropion Sustained Release, Drug: Varenicline, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion | Intervention Type: DRUG; Name: Nicotine replacement therapy - transdermal nicotine patch; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Tailored behavioral intervention; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Tobacco quit line referral; Assigned to Arm(s): Enhanced Standard of Care Group | Intervention Type: DRUG; Name: Nicotine replacement therapy - nicotine gum; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Nicotine replacement therapy - nicotine lozenge; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Bupropion Sustained Release; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + bupropion; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Alcohol use risk reduction; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Behavioral activation for the treatment of depression; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Behavioral management of post-cessation weight gain; Assigned to Arm(s): Tailored Intervention Group",
"D": "Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00018174",
"NCT01444131",
"NCT01592695",
"NCT00176449"
] | 364 |
train
|
NCT00018174
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
Brief Summary: This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"B": "Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban",
"C": "Arm Label: Varenicline + Placebo Patch; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Placebo Patch, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Arm Label: Nicotine Patch + Placebo Tablet; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: DRUG; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Placebo Tablet; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: BEHAVIORAL; Name: Counseling Sessions; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Lab Session; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Saliva Test; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch",
"D": "Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management"
}
|
A
|
[
"NCT00018174",
"NCT01806779",
"NCT02162849",
"NCT00330187"
] | 365 |
train
|
NCT00018174
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
Brief Summary: This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
|
{
"A": "Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline",
"B": "Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"D": "Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4"
}
|
C
|
[
"NCT00285012",
"NCT01370356",
"NCT00018174",
"NCT02147132"
] | 366 |
train
|
NCT00018655
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Intervention for Substance Abusers With Depressive Disorders
Brief Summary: This study is a randomized clinical trial comparing outcomes of Integrated Cognitive Behavioral Treatment plus standard medications for veterans with both substance use disorders, depressive disorders versus the most commonly administered form of therapy for substance use disorders and depression, Twelve Step Facilitation (AA/NA model) group treatment plus medications.
|
{
"A": "Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care",
"B": "Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2",
"D": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Twelve Step Facilitation | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Cognitive Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Twelve Step Facilitation; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Integrated Cognitive Behavioral Treatment; Assigned to Arm(s): Arm 2"
}
|
D
|
[
"NCT01941693",
"NCT00218634",
"NCT00809770",
"NCT00018655"
] | 367 |
train
|
NCT00018902
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)
Brief Summary: The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
|
{
"A": "Arm Label: IPT+antidepressant drugs; Type: EXPERIMENTAL; Interventions: Other: IPT+ antidepressant drugs, Drug: fluoxetine, Drug: sertraline, Drug: paroxetine, Drug: Citalopram, Drug: escitalopram, Drug: fluvoxamine, Drug: Venlafaxine, Drug: Duloxetine, Drug: Bupropion, Drug: Lithium, Drug: Risperidone, Drug: tranylcypromine, Drug: Imipramine, Drug: amitriptyline, Drug: Clomipramine, Drug: nortriptyline, Drug: trazodone, Drug: Mirtazapine, Drug: sulpiride | Arm Label: Antidepressant Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine, Drug: sertraline, Drug: paroxetine, Drug: Citalopram, Drug: escitalopram, Drug: fluvoxamine, Drug: Venlafaxine, Drug: Duloxetine, Drug: Bupropion, Drug: Lithium, Drug: Risperidone, Drug: tranylcypromine, Drug: Imipramine, Drug: amitriptyline, Drug: Clomipramine, Drug: nortriptyline, Drug: trazodone, Drug: Mirtazapine, Drug: sulpiride | Intervention Type: OTHER; Name: IPT+ antidepressant drugs; Assigned to Arm(s): IPT+antidepressant drugs | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: fluvoxamine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Imipramine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: amitriptyline; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Clomipramine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: trazodone; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs | Intervention Type: DRUG; Name: sulpiride; Assigned to Arm(s): Antidepressant Drugs, IPT+antidepressant drugs",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3",
"C": "Intervention Type: BEHAVIORAL; Name: Control with depression course (CWD); Assigned to Arm(s): N/A",
"D": "Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Analysis System of Psychotherapy | Arm Label: SYSP; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: System of Supportive Psychotherapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BEHAVIORAL; Name: System of Supportive Psychotherapy; Assigned to Arm(s): SYSP"
}
|
B
|
[
"NCT01896349",
"NCT00018902",
"NCT00319540",
"NCT00970437"
] | 368 |
train
|
NCT00018902
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)
Brief Summary: The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3",
"B": "Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavioral therapy for adolescents (DBT-A) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Dialectical behavioral therapy for adolescents (DBT-A); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): 2",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3"
}
|
D
|
[
"NCT00110461",
"NCT00006286",
"NCT00675129",
"NCT00018902"
] | 369 |
train
|
NCT00018902
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)
Brief Summary: The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3",
"D": "Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT00050557",
"NCT00158301",
"NCT00018902",
"NCT00508859"
] | 370 |
train
|
NCT00018902
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)
Brief Summary: The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3",
"B": "Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2"
}
|
A
|
[
"NCT00018902",
"NCT00107120",
"NCT00006286",
"NCT00158301"
] | 371 |
train
|
NCT00019682
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Brief Summary: This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person's white blood cells to kill melanoma cells. Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining aldesleukin with vaccine therapy is more effective than aldesleukin alone in treating melanoma.
|
{
"A": "Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine, Drug: Interferon Alfa-2b | Arm Label: B1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Arm Label: B2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): A1, A2, B1, B2 | Intervention Type: DRUG; Name: Fotemustine; Assigned to Arm(s): A1, A2 | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): A2, B2",
"B": "Arm Label: Nivolumab, 3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (Nivolumab), Drug: Placebo matching Dacarbazine | Arm Label: Dacarbazine, 1000 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo matching BMS-936558 (Nivolumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: BMS-936558 (Nivolumab); Assigned to Arm(s): Nivolumab, 3 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo matching BMS-936558 (Nivolumab); Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Placebo matching Dacarbazine; Assigned to Arm(s): Nivolumab, 3 mg/kg",
"C": "Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab",
"D": "Arm Label: Arm I (aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: gp100 Antigen, Drug: Montanide ISA 51 VG, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: BIOLOGICAL; Name: gp100 Antigen; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: DRUG; Name: Montanide ISA 51 VG; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)"
}
|
D
|
[
"NCT01359956",
"NCT01721772",
"NCT02858921",
"NCT00019682"
] | 372 |
train
|
NCT00019695
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate
Brief Summary: RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium.
PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.
|
{
"A": "Intervention Type: DRUG; Name: alendronate sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ketoconazole; Assigned to Arm(s): N/A",
"B": "Arm Label: IV Bisphosphonates q 4 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Bisphosphonate q 4 weeks | Arm Label: 180 mg AMG 162 (SC) q 12 weeks; Type: EXPERIMENTAL; Interventions: Genetic: AMG 162 180 mg (SC) q 12 weeks | Arm Label: 180 mg AMG 162 (SC) q 4 weeks; Type: EXPERIMENTAL; Interventions: Genetic: AMG 162- 180 mg q 4 weeks | Intervention Type: GENETIC; Name: AMG 162 180 mg (SC) q 12 weeks; Assigned to Arm(s): 180 mg AMG 162 (SC) q 12 weeks | Intervention Type: DRUG; Name: IV Bisphosphonate q 4 weeks; Assigned to Arm(s): IV Bisphosphonates q 4 weeks | Intervention Type: GENETIC; Name: AMG 162- 180 mg q 4 weeks; Assigned to Arm(s): 180 mg AMG 162 (SC) q 4 weeks",
"C": "Arm Label: Zoledronic acid + androgen deprivation therapy; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid, Drug: androgen deprivation therapy, Drug: GnRH agonist, Dietary Supplement: Calcium supplement, Dietary Supplement: Vitamin D | Arm Label: Placebo + androgen deprivation therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo, Drug: androgen deprivation therapy, Drug: GnRH agonist, Dietary Supplement: Calcium supplement, Dietary Supplement: Vitamin D | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronic acid + androgen deprivation therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo + androgen deprivation therapy | Intervention Type: DRUG; Name: androgen deprivation therapy; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium supplement; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy",
"D": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: antiandrogen therapy, Drug: zoledronic acid | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: antiandrogen therapy | Intervention Type: DRUG; Name: antiandrogen therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Arm I"
}
|
A
|
[
"NCT00019695",
"NCT00104650",
"NCT00079001",
"NCT00685646"
] | 373 |
train
|
NCT00020566
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without radiation therapy and/or surgery in treating Ewing's sarcoma.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.
|
{
"A": "Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy",
"B": "Arm Label: Part A, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part A, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Methotrexate | Arm Label: Part B, Group 3; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 4; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 50 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 5; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 25 mg, Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 136 100 mg; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3 | Intervention Type: DRUG; Name: CNTO 136 50 mg; Assigned to Arm(s): Part B, Group 4 | Intervention Type: DRUG; Name: CNTO 136 25 mg; Assigned to Arm(s): Part B, Group 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 3, Part B, Group 4, Part B, Group 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3, Part B, Group 4, Part B, Group 5",
"C": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Group 2, arm I; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Group 2, arm II; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: busulfan, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: melphalan, Drug: vincristine sulfate, Procedure: autologous hematopoietic stem cell transplantation, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: dactinomycin; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): Group 2, arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 2, arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 2, arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II",
"D": "Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab"
}
|
C
|
[
"NCT00334594",
"NCT00718718",
"NCT00020566",
"NCT01655888"
] | 374 |
train
|
NCT00021060
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC
Brief Summary: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill more tumor cells. This randomized phase II/III trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have advanced, metastatic, or recurrent non-small cell lung cance
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: bevacizumab [Avastin] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: bevacizumab [Avastin] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 2",
"B": "Arm Label: Arm I (paclitaxel and carboplatin); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Other: laboratory biomarker analysis | Arm Label: Arm II (paclitaxel, carboplatin, and bevacizumab); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Biological: bevacizumab, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab)",
"C": "Arm Label: Pemetrexed + Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Pemetrexed + Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Carboplatin, Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pemetrexed + Carboplatin",
"D": "Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Arm Label: Paclitaxel+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Gemcitabine+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine | Arm Label: Gemcitabine+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel+Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Gemcitabine+Carboplatin, Paclitaxel+Carboplatin, Pemetrexed+Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Paclitaxel+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine+Cisplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine+Carboplatin, Gemcitabine+Cisplatin"
}
|
B
|
[
"NCT00806923",
"NCT00021060",
"NCT00402051",
"NCT02142738"
] | 375 |
train
|
NCT00021060
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC
Brief Summary: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill more tumor cells. This randomized phase II/III trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have advanced, metastatic, or recurrent non-small cell lung cance
|
{
"A": "Arm Label: Arm I (paclitaxel and carboplatin); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Other: laboratory biomarker analysis | Arm Label: Arm II (paclitaxel, carboplatin, and bevacizumab); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Biological: bevacizumab, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab)",
"B": "Arm Label: Paclitaxel + Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, Drug: Paclitaxel | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel, Paclitaxel + Bevacizumab",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4",
"D": "Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00021060",
"NCT00028990",
"NCT00593450",
"NCT00088283"
] | 376 |
train
|
NCT00021255
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration
Brief Summary: Primary objective:
* Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin.
Secondary objective:
* Compare overall survival of participants treated with these regimens.
* Compare the toxic effects (including cardiac) of these regimens in these participants.
* Compare quality of life of participants treated with these regimens.
* Compare pathologic and molecular markers for predicting efficacy of these regimens in these participants.
* For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in participants treated with these regimens.
|
{
"A": "Arm Label: Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate | Arm Label: Arm II (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Arm Label: Arm III (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Intervention Type: DRUG; Name: Aromatase Inhibition Therapy; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Tamoxifen Citrate; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: BIOLOGICAL; Name: Trastuzumab; Assigned to Arm(s): Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen)",
"B": "Arm Label: Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Docetaxel | Arm Label: AC followed by Docetaxel + Herceptin (AC→TH); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Docetaxel, Drug: Herceptin | Arm Label: Docetaxel + Carboplatin + Herceptin (TCH); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Herceptin, Drug: Carboplatin | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Docetaxel + Carboplatin + Herceptin (TCH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Docetaxel + Carboplatin + Herceptin (TCH) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Docetaxel + Carboplatin + Herceptin (TCH)",
"C": "Arm Label: Observation Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herceptin 1-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Arm Label: Herceptin 2-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 1-Year Arm | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 2-Year Arm",
"D": "Arm Label: Arm 1: adriamycin + cyclophosphamide then taxol; Type: ACTIVE_COMPARATOR; Interventions: Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Arm Label: Arm 2: adriamycin + cyclophosphamide then taxol + herceptin; Type: EXPERIMENTAL; Interventions: Biological: herceptin, Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Intervention Type: BIOLOGICAL; Name: herceptin; Assigned to Arm(s): Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: adriamycin; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: taxol; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin"
}
|
B
|
[
"NCT00005970",
"NCT00021255",
"NCT00045032",
"NCT00004067"
] | 377 |
train
|
NCT00021476
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Chronic Whiplash Pain: Biobehavioral Approach
Brief Summary: This study is aimed at developing ways to prevent acute pain from becoming chronic pain--specifically, pain associated with whiplash-associated disorders (WADs) from motor vehicle accidents. Research on the development of chronic pain due to musculoskeletal injury suggests that a person's initial emotional reactions, particularly fear of reinjury and subsequent avoidance of activity, contribute significantly to chronic pain and persistent disability. This study will treat people with WADs during the first three months after a motor vehicle accident with a behavioral and physical exercise program designed to encourage activity and discourage continued fear of movement, pain, and disability. The study will compare the effectiveness of two anxiety-reduction treatments to standard care in reducing pain and activity limitations in people with WADs in the 2 to 3 months after motor vehicle accidents.
|
{
"A": "Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program",
"B": "Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: Behavioral treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physical therapy; Assigned to Arm(s): N/A",
"D": "Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00551980",
"NCT00029770",
"NCT00021476",
"NCT00488735"
] | 378 |
train
|
NCT00021528
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
|
{
"A": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine-XR | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Venlafaxine-XR; Assigned to Arm(s): C",
"B": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine | Arm Label: C; Type: SHAM_COMPARATOR; Interventions: Other: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine | Intervention Type: OTHER; Name: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed; Assigned to Arm(s): A | Intervention Type: OTHER; Name: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine; Assigned to Arm(s): B | Intervention Type: OTHER; Name: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine; Assigned to Arm(s): C",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2"
}
|
B
|
[
"NCT00693849",
"NCT00021528",
"NCT00714090",
"NCT00368550"
] | 379 |
train
|
NCT00021528
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
|
{
"A": "Arm Label: Internet-based stepped care; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based stepped care | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based stepped care; Assigned to Arm(s): Internet-based stepped care",
"B": "Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm",
"C": "Arm Label: FitNet treatment; Type: EXPERIMENTAL; Interventions: Behavioral: FitNet treatment | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: FitNet treatment; Assigned to Arm(s): FitNet treatment | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care",
"D": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT01630681",
"NCT00280319",
"NCT00893438",
"NCT00021528"
] | 380 |
train
|
NCT00021528
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
|
{
"A": "Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A",
"C": "Arm Label: Less Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: More Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Less Dependent Smokers, More Dependent Smokers",
"D": "Arm Label: Nicotine Replacement Therapy Responder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patches | Arm Label: Pre-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit) | Arm Label: Pre-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Pre-Quit) | Arm Label: Pre-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Pre-Quit) | Arm Label: Post-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit) | Arm Label: Post-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Post-Quit) | Arm Label: Post-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Post-Quit) | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Replacement Therapy Responder | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Nicotine"
}
|
B
|
[
"NCT00141206",
"NCT00021528",
"NCT00734617",
"NCT00894166"
] | 381 |
train
|
NCT00021528
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
|
{
"A": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A",
"B": "Arm Label: Vilazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilazodone | Arm Label: Citalopram; Type: PLACEBO_COMPARATOR; Interventions: Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram",
"C": "Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg",
"D": "Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2"
}
|
A
|
[
"NCT00021528",
"NCT01742832",
"NCT02015546",
"NCT00105196"
] | 382 |
train
|
NCT00021528
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
|
{
"A": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A",
"B": "Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Standard of Community Care Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Community Care Treatment | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Standard of Community Care Treatment; Assigned to Arm(s): Standard of Community Care Treatment",
"C": "Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Supportive Non-Directive Therapy (SNDT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Non-directive Therapy (SNDT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Supportive Non-directive Therapy (SNDT); Assigned to Arm(s): Supportive Non-Directive Therapy (SNDT)",
"D": "Arm Label: Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BFST | Arm Label: Skype; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BFST | Intervention Type: BEHAVIORAL; Name: BFST; Assigned to Arm(s): Clinic, Skype"
}
|
A
|
[
"NCT00021528",
"NCT00446238",
"NCT00534911",
"NCT02274103"
] | 383 |
train
|
NCT00021528
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
|
{
"A": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1",
"B": "Arm Label: Citalopram + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pindolol | Arm Label: Citalopram + pindolol; Type: EXPERIMENTAL; Interventions: Drug: Pindolol | Intervention Type: DRUG; Name: Pindolol; Assigned to Arm(s): Citalopram + pindolol, Citalopram + placebo",
"C": "Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo",
"D": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00162916",
"NCT00931775",
"NCT00071643",
"NCT00021528"
] | 384 |
train
|
NCT00022750
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project Sugar 2: Health Events Costs in Diabetic Blacks
Brief Summary: Diabetes mellitus imposes a major burden on the public health of the United States, leading annually to over 300,000 deaths and over $130 billion in costs. This burden falls disproportionately upon ethnic minority groups, particularly African Americans, who are at excess risk for the development of type 2 diabetes and for a variety of its most serious complications. Suboptimal health care - in terms of access, quality, and adherence -appears to be an important contributing factor. Prior work suggests two possible approaches aimed at prevention to enhance risk factor control in outpatients with type 2 diabetes. One approach uses Nurse Case Managers (NCMs) to coordinate care plans with the provider team following protocols/clinical guidelines and algorithms designed to guide treatment including initiating and adjusting drug therapy, enhancing continuity of care, promoting interventions and self-management which include educational and behavioral strategies incorporating feedback and self-regulation. Another approach uses Community Health Workers (CHWs) to enhance culturally sensitive outreach, linkage, and monitoring service; to provide important patient and family education; and to improve access to and continuity of care. Results indicate that this intensive team approach, compared to usual care alone, produces substantial improvements in metabolic control. However, the cost-effectiveness of such interventions is unknown in the ''real-world''.
This has led to our current study, a randomized controlled trial within a managed care organization to determine the effects of a NCM/CHW team on metabolic control, on the occurrence of diabetes-related health events, health care utilization, and on direct health care costs. The participants will be African American adults with type 2 diabetes who receive primary care within a managed care organization in inner-city Baltimore.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: Nurse Case Manager and Community Health Worker Team; Assigned to Arm(s): N/A",
"B": "Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling",
"C": "Arm Label: Integrated Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Behavioral Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Behavioral Care; Assigned to Arm(s): Integrated Behavioral Intervention",
"D": "Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Arm Label: Late implementation; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Early Intervention | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Late implementation"
}
|
A
|
[
"NCT00022750",
"NCT01264796",
"NCT02863523",
"NCT02299791"
] | 385 |
train
|
NCT00022776
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Treatment for Spinal Stenosis
Brief Summary: Lumbar spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) is a condition that occurs frequently, particularly in the elderly. This condition can lead to significant pain and limit a person's ability to function. Moreover, doctors disagree about the best way to treat people with lumbar spinal stenosis.
In this study we will compare surgical treatment of lumbar spinal stenosis with nonsurgical treatment using physical therapy. The results of this study should help clarify which treatment strategies are the most effective for patients with lumbar spinal stenosis.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lumbar Laminectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion | Intervention Type: PROCEDURE; Name: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lumbar Laminectomy; Assigned to Arm(s): 1",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2",
"C": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery",
"D": "Arm Label: Decompression without fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression without fusion | Arm Label: Decompression with fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression with fusion | Intervention Type: PROCEDURE; Name: Decompression without fusion; Assigned to Arm(s): Decompression without fusion | Intervention Type: PROCEDURE; Name: Decompression with fusion; Assigned to Arm(s): Decompression with fusion"
}
|
B
|
[
"NCT00109213",
"NCT00022776",
"NCT00000411",
"NCT01994512"
] | 386 |
train
|
NCT00022776
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Treatment for Spinal Stenosis
Brief Summary: Lumbar spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) is a condition that occurs frequently, particularly in the elderly. This condition can lead to significant pain and limit a person's ability to function. Moreover, doctors disagree about the best way to treat people with lumbar spinal stenosis.
In this study we will compare surgical treatment of lumbar spinal stenosis with nonsurgical treatment using physical therapy. The results of this study should help clarify which treatment strategies are the most effective for patients with lumbar spinal stenosis.
|
{
"A": "Arm Label: Vertos mild® Minimally-Invasive Lumbar Decompression; Type: ACTIVE_COMPARATOR; Interventions: Device: MILD® (Minimally Invasive Lumbar Decompression) | Arm Label: Epidural Steroid Injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epidural Steroid Injection | Intervention Type: DEVICE; Name: MILD® (Minimally Invasive Lumbar Decompression); Assigned to Arm(s): Vertos mild® Minimally-Invasive Lumbar Decompression | Intervention Type: DRUG; Name: Epidural Steroid Injection; Assigned to Arm(s): Epidural Steroid Injection",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2",
"C": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery",
"D": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery"
}
|
B
|
[
"NCT00995371",
"NCT00022776",
"NCT00000411",
"NCT00000409"
] | 387 |
train
|
NCT00023283
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Counseling Conditions for Thrice Weekly Buprenorphine in a Primary Care Clinic
Brief Summary: The purpose of this study is to compare the Standard Medical Management (SMM) vs. SMM enhanced with additional education about addiction and recovery (Enhanced Medical Management, EMM)
|
{
"A": "Arm Label: Methadone; Type: OTHER; Interventions: Drug: Methadone | Arm Label: Buprenorphine/Naloxone; Type: OTHER; Interventions: Drug: Buprenorphine-Naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine-Naloxone; Assigned to Arm(s): Buprenorphine/Naloxone",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): 1, 2, 3",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2",
"D": "Arm Label: RBP-6000 300mg/100mg; Type: EXPERIMENTAL; Interventions: Drug: SUBOXONE, Drug: RBP-6000 | Arm Label: RBP-6000 300mg/300mg; Type: EXPERIMENTAL; Interventions: Drug: SUBOXONE, Drug: RBP-6000 | Arm Label: Placebo Matching 300 mg/100 mg RBP-6000; Type: PLACEBO_COMPARATOR; Interventions: Drug: SUBOXONE, Drug: Placebo | Arm Label: Placebo Matching 300 mg RBP-6000; Type: PLACEBO_COMPARATOR; Interventions: Drug: SUBOXONE, Drug: Placebo | Intervention Type: DRUG; Name: SUBOXONE; Assigned to Arm(s): Placebo Matching 300 mg RBP-6000, Placebo Matching 300 mg/100 mg RBP-6000, RBP-6000 300mg/100mg, RBP-6000 300mg/300mg | Intervention Type: DRUG; Name: RBP-6000; Assigned to Arm(s): RBP-6000 300mg/100mg, RBP-6000 300mg/300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Matching 300 mg RBP-6000, Placebo Matching 300 mg/100 mg RBP-6000"
}
|
B
|
[
"NCT03033732",
"NCT00023283",
"NCT00555425",
"NCT02357901"
] | 388 |
train
|
NCT00023452
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Brief Summary: Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).
|
{
"A": "Arm Label: Daily Isoniazid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid (INH) daily for 9 months | Arm Label: Weekly Isoniazid / Rifapentine; Type: EXPERIMENTAL; Interventions: Drug: RPT + INH once weekly for 3 months given by DOT | Intervention Type: DRUG; Name: RPT + INH once weekly for 3 months given by DOT; Assigned to Arm(s): Weekly Isoniazid / Rifapentine | Intervention Type: DRUG; Name: Isoniazid (INH) daily for 9 months; Assigned to Arm(s): Daily Isoniazid",
"B": "Arm Label: Isoniazid preventive therapy; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Cotrimoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cotrimoxazole, Other: placebo | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): Isoniazid preventive therapy, Placebo | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Isoniazid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: Rifampin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifampin | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): Rifampin",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifapentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rifapentine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): 2"
}
|
A
|
[
"NCT00023452",
"NCT00330304",
"NCT00170209",
"NCT00057122"
] | 389 |
train
|
NCT00024102
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways after surgery may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating older women with breast cancer.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work in treating older women who have undergone surgery for breast cancer.
|
{
"A": "Arm Label: A (experimental group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Capecitabine, Drug: Trastuzumab | Arm Label: B (control group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A (experimental group) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): A (experimental group), B (control group)",
"B": "Arm Label: Standard Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Treatment | Arm Label: Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: capecitabine | Intervention Type: DRUG; Name: Standard Treatment; Assigned to Arm(s): Standard Chemotherapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Capecitabine",
"C": "Arm Label: Arm 1A: Docetaxel then AC; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 1B Docetaxel + Bev then AC + Bev; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 2A: Docetaxel + Capecitabine then AC; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 2B: Docetaxel + Cape + Bev then AC + Bev; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: capecitabine, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin) | Arm Label: Arm 3A: Docetaxel + Gem then AC; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin), Drug: gemcitabine hydrochloride | Arm Label: Arm 3B: Docetaxel + Gem + Bev then AC + Bev; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: cyclophosphamide, Drug: docetaxel, Drug: doxorubicin hydrochloride (Adriamycin), Drug: gemcitabine hydrochloride | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm 1B Docetaxel + Bev then AC + Bev, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1A: Docetaxel then AC, Arm 1B Docetaxel + Bev then AC + Bev, Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1A: Docetaxel then AC, Arm 1B Docetaxel + Bev then AC + Bev, Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: doxorubicin hydrochloride (Adriamycin); Assigned to Arm(s): Arm 1A: Docetaxel then AC, Arm 1B Docetaxel + Bev then AC + Bev, Arm 2A: Docetaxel + Capecitabine then AC, Arm 2B: Docetaxel + Cape + Bev then AC + Bev, Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Arm 3A: Docetaxel + Gem then AC, Arm 3B: Docetaxel + Gem + Bev then AC + Bev",
"D": "Arm Label: A Bev+Pac; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab and Paclitaxel | Arm Label: B Bev+Cap; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab and Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab and Paclitaxel; Assigned to Arm(s): A Bev+Pac | Intervention Type: BIOLOGICAL; Name: Bevacizumab and Capecitabine; Assigned to Arm(s): B Bev+Cap"
}
|
B
|
[
"NCT00309556",
"NCT00024102",
"NCT00408408",
"NCT00600340"
] | 390 |
train
|
NCT00025259
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease
Brief Summary: This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
|
{
"A": "Arm Label: novel stent; Type: ACTIVE_COMPARATOR; Interventions: Device: novel stent | Arm Label: conventional covered stent; Type: EXPERIMENTAL; Interventions: Device: conventional covered stent | Intervention Type: DEVICE; Name: novel stent; Assigned to Arm(s): novel stent | Intervention Type: DEVICE; Name: conventional covered stent; Assigned to Arm(s): conventional covered stent",
"B": "Arm Label: Arm I (Patients off-therapy before callback-Induction only); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm II (RER with CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm III (RER with CR [ABVE-PC]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm IV (RER with less than CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm V (RER with PD); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VI (SER [DECA, ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VII (SER [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: RADIATION; Name: Involved-Field Radiation Therapy; Assigned to Arm(s): Arm II (RER with CR [ABVE-PC, IFRT]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Vincristine Sulfate Liposome; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT])",
"C": "Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy",
"D": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: isolated perfusion; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT01054274",
"NCT00025259",
"NCT00334594",
"NCT00002641"
] | 391 |
train
|
NCT00025259
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease
Brief Summary: This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
|
{
"A": "Arm Label: Arm I (Patients off-therapy before callback-Induction only); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm II (RER with CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm III (RER with CR [ABVE-PC]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm IV (RER with less than CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm V (RER with PD); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VI (SER [DECA, ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VII (SER [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: RADIATION; Name: Involved-Field Radiation Therapy; Assigned to Arm(s): Arm II (RER with CR [ABVE-PC, IFRT]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Vincristine Sulfate Liposome; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT])",
"B": "Arm Label: Radiotherapy or ABVD + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine, Radiation: radiation therapy | Arm Label: ABVD Alone; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiotherapy or ABVD + Radiotherapy",
"C": "Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome",
"D": "Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D"
}
|
A
|
[
"NCT00025259",
"NCT00002561",
"NCT00433433",
"NCT00265018"
] | 392 |
train
|
NCT00025779
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders
Brief Summary: This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
|
{
"A": "Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole",
"C": "Arm Label: Arbaclofen; Type: EXPERIMENTAL; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00025779",
"NCT01617447",
"NCT03682978",
"NCT00004486"
] | 393 |
train
|
NCT00025779
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders
Brief Summary: This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
|
{
"A": "Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A",
"C": "Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo",
"D": "Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo"
}
|
B
|
[
"NCT00490802",
"NCT00025779",
"NCT00365859",
"NCT00086645"
] | 394 |
train
|
NCT00025779
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders
Brief Summary: This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
|
{
"A": "Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline",
"B": "Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT01098383",
"NCT00468130",
"NCT00025779",
"NCT00252603"
] | 395 |
train
|
NCT00025935
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Characterization and Pathophysiology of Severe Mood and Behavioral Dysregulation in Children and Youth
Brief Summary: This study seeks to learn more about the symptoms of severe mood dysregulation in children and adolescents ages 7-17. Children and adolescents with severe mood dysregulation (SMD) display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme responses to frustration (such as frequent, severe temper tantrums). Researchers will describe the moods and behaviors of children with these symptoms and use specialized testing and brain imaging to learn about the brain changes associated with this disorder....
|
{
"A": "Arm Label: PBS based staff training; Type: EXPERIMENTAL; Interventions: Behavioral: PBS based staff training, Other: Treatment as Usual | Arm Label: Treatment as usual; Type: OTHER; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: PBS based staff training; Assigned to Arm(s): PBS based staff training | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): PBS based staff training, Treatment as usual",
"B": "Arm Label: Children/adolescents with ADHD; Type: N/A; Interventions: Drug: Lithium | Arm Label: Children/Adolescents with DMDD or subthreshold DMDD; Type: N/A; Interventions: Drug: Lithium | Arm Label: Children/adolescents with MDD; Type: N/A; Interventions: N/A | Arm Label: Healthy volunteer adults; Type: N/A; Interventions: N/A | Arm Label: Healthy volunteer children/adolescents; Type: N/A; Interventions: N/A | Arm Label: Parents of children/adolescents with DMDD or subthreshold DMDD; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Children/Adolescents with DMDD or subthreshold DMDD, Children/adolescents with ADHD",
"C": "Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Behavior analytic treatment | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavior analytic treatment; Assigned to Arm(s): Treatment",
"D": "Arm Label: Cognitus and Me; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive remediation program | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive remediation program | Intervention Type: BEHAVIORAL; Name: Cognitive remediation program; Assigned to Arm(s): Cognitus and Me, control group"
}
|
B
|
[
"NCT01680276",
"NCT00025935",
"NCT03510156",
"NCT02797418"
] | 396 |
train
|
NCT00026312
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Brief Summary: This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.
|
{
"A": "Arm Label: Arm I (temozolomide, irinotecan hydrochloride, temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: Irinotecan Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Temozolomide, Drug: Temsirolimus | Arm Label: Arm II (temozolomide, irinotecan hydrochloride, dinutuximab); Type: EXPERIMENTAL; Interventions: Biological: Dinutuximab, Drug: Irinotecan Hydrochloride, Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Drug: Temozolomide | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Irinotecan Hydrochloride; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)",
"B": "Arm Label: Arm I (isotretinoin) (closed to accrual as of 4/16/2009); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: Dinutuximab, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Biological: Sargramostim | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: DRUG; Name: Isotretinoin; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)",
"C": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Anti-GD2 antibody | Intervention Type: BIOLOGICAL; Name: Anti-GD2 antibody; Assigned to Arm(s): Group 1",
"D": "Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT"
}
|
B
|
[
"NCT01767194",
"NCT00026312",
"NCT00743496",
"NCT01704716"
] | 397 |
train
|
NCT00026312
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Brief Summary: This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.
|
{
"A": "Arm Label: Arm I (isotretinoin) (closed to accrual as of 4/16/2009); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: Dinutuximab, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Biological: Sargramostim | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: DRUG; Name: Isotretinoin; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)",
"B": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"C": "Arm Label: Arm I (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Arm Label: Arm II (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm I (unpurged PBSC collection) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: isotretinoin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: topotecan hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: bone marrow ablation with stem cell support; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection)",
"D": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00026312",
"NCT00017225",
"NCT00004188",
"NCT00002803"
] | 398 |
train
|
NCT00027053
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trazodone for Sleep Disturbance - Early Alcohol Recovery
Brief Summary: This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an inpatient detoxification program. Subjects will undergo a baseline assessment and random assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.)
|
{
"A": "Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + CBT-I | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT-I plus placebo antidepressant medication | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram + CBT-I; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: CBT-I plus placebo antidepressant medication; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 3",
"C": "Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo"
}
|
C
|
[
"NCT00370656",
"NCT00620789",
"NCT00027053",
"NCT01234675"
] | 399 |
train
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.